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Summary 
Improvement of anti-tumor biotherapy effectiveness by modification of immune response with 
histamine H2 receptor Cimetidinum (CM) was studied using the experimental murine model of 
B16 F10 melanoma in vivo. It is shown that skin melanoma biotherapy by antitumor whole-cell 
GM-CSF-producing vaccine with the addition of CM (in dose of 25 mg/kg, daily for 5 days) 
increases preventive effects of vaccination. 33 % of mice did not have tumor growth within 60 
days of observation. Average life span of animals exceeded those of the control group up to 68 
%. Using CM-combined bio-chemotherapy doesn't improve therapeutic effect, however in the 
case of a monotherapeutic approach tendency for increased average life-time and decreased 
metastatic processes in mice with the developed tumors was noticed. Aquired data provides 
expediency to study the further application of CM as adjuvant for skin melanoma 
vaccinotherapy, and also the necessity to verify the immune status of an organism against the 
complex bio-chemotherapy. 
Key words: melanoma, Cimetidinum, biotherapy, antitumor cell-whole GM-CSF-producing 
vaccine. 
INTRODUCTION 
Changing of Th1/Th2 equilibrium leads to significant changes of immune reactions in 
patients with skin melanoma [1,2]. The patients with metastatic melanoma of 3-4 stages have the 
Th2 immune chronic inflammation. The increase of IL 4,5,6,9,10 cytokine and histamine 
concentrations result in disease progression and to an increase in metastatic process 
[5,6,7,8,9,10,11,12]; while Th1 immune profile correlates with propitious forecast of the disease 
[5,6,7].  It gives us an opportunity to model various immune reactions for increasing the efficacy 
of skin melanoma therapy utilizing concept approaches of allergooncology [13]. 
While describing histamine importance in the immune reactions it is necessary to focus 
our attention on following [14,15]: 1) lymphocytes express 2 types of histamine receptors: H1-R, 
H2-R; 2) histamine interaction with G-protein coupled H1-R leads to activation of immune 
reaction by means of T-cell or B-cell receptors; 3) histamine action through receptor H2-R is 
realized by adenylatecyclase, and leads to subsequent elevation of intercellular cAMP levels and 
to reversing immunosuppressive effect; 4) H1-R is expressed exclusively by Th1 cells; Th2 cells 
have both H1-R and H2-R on their surface. Besides histamine is characterized by the stimulatory 
effect on cytotoxic CD8+ T lymphocytes and the suppressive H2-R-mediated influence on the 
NK; 5) histamine effect on different population of lymphocytes can be realized by monocytes 
which react to it by increased production of immunoregulatory IL18 and IFN alongside with a 
decrease in producing of active forms of oxygen and phagocytic activity; 6) histamine effect on 
macrophages cancels of the inhibitory macrophage effects through active forms of oxygen on T 
lymphocytes and NK cells; 7) endogenous histamine influences the expression of surface 
receptors and adhesion molecules in immune cells [16,17]. Histamine takes part in inflammation 
and reparation processes by increasing vascular penetration; activates cytokine cascade and 
stimulates immune cells function, stroma cells function and stimulates angiogenesis. As for 
oncogenesis, histamine can stimulate proliferation and tumor angiogenesis process increasing 
tumor growth [18].  
There are histamine receptors on the surface of both normal cells and tumor cells where 
their biological functions are not clear so far. In same investigations it was shown that histamine 
does not only stimulate tumor cell proliferation, but is also chemotoxic to both human cancer 
(Hela and A431) and melanoma (A875) containing H1-R [19]. 
Considering that the effects caused by histamine can be blocked by H-R antagonists, in 
1970-1980 the influence of H-R antagonists as pharmacological instruments of influence on the 
types and kinetics of immune reactions were studied. Cimetidinum (CM) was used as a standard 
drug. Immune-regulating potencies of H2-R antagonists have the following order: Cimetidinum> 
Ranitidinum>Famotidinum. CM is able to directly block H2-R and indirectly block H1-R 
[20,21]. 
Applying CM for 7 days per os to healthy donors resulted in leukocytosis, neutrophilia, 
increase in CD3+ Tl population CD4+ cells. The number of NK cells decreased while the 
number of NKT cells did not change [22]. Small dozes of histamine H2-inhibitors stimulate sIgA 
synthesis and thus activating “macrophages-fibroblasts” system [23,24]. 
CM realizes its activity by blocking tumor angiogenesis and retarding cancer cell 
proliferation. CM also realizes its activity by increasing lymphocytes activity and in such a way 
it decreases the function of Tl suppressors. It increases antitumor immune reaction of the whole 
organism by retarding histamine activity as of a tumor growth factor, by increasing IL2 level, 
and Ig production [25,26]. CM lowers skin EGF (epidermis growth factor) by decreasing 
intracellular cATP level [27].  
CM counteracts IL-1 inducted activation of adhesion molecules in endothelial vascular 
cells as well as in liver sinusoids. CM significantly decreases A-selectin protein expression 
without altering its at mRNA expression levels in cells, which can prevent hematogenic 
metastasis [28]. However, it is shown that after CM cessation the E-selectin level increases again 
[29]. 
Antitumor and immune regulating CM activity was first studied in patients with GI 
cancers. Taking into consideration good results from these studies, the similar investigations of 
CM functions were undertaken on tumors of other tissues, which contained a big number of 
histamine producing cells. 
CM by means of activating immune system cells and increasing antitumor T-cells 
response improved the prognosis and increased GI cancer patients survivability after surgical 
treatment as well as in combination with chemical therapy of non-operable colonic and rectum 4 
stage cancers [17,30].   
CM is able to affect on caspase cascade activation in vitro, including 8, 9, 3 caspases. It is 
shown that, in this case, expression of Bcl protein is decreased while Bac protein expression is 
increased. Thus CM is able to induce apoptosis in tumor cells [31].  
Experiments on SCID mice treated with CM it have shown growth inhibition of pancreas 
tumor cells xenotransplantants [32,33]. CM significantly reduced the development of metastases 
and increased life span of mice with neoblastoma and glioma during the experiment [34,35,36].  
It was also shown that CM is able to slightly increase TCGF production after PHA-P 
activation. More of all, CM significantly increased TCGF-activated PBL protein proliferation. 
This effect was demonstrated in patients with skin melanoma who had initially low Tl activity.  
Skin and melanoma cells have significant levels of histamine and express histamine 
receptors, indicating on the existence of autocrine and paracrine histamine regulation. In 
melanoma cells histamine increases intracellular cATP concentration and stimulates melanoma 
cell growth and metastasis progress [37,38]. It is demonstrated that histamine increases 
melanoma cell growth mainly through H2-R. Tumor progression decreases in SCID mice with 
HT168 human melanoma xanotransplantant melanoma cell line in vivo with combined CM and 
tamoxifen derivative therapy regulating P453 cytochrome (DPPE). Such regulations are 
associated with an increase in gIFN levels and an increase of infiltration of tumor tissue by 
macrophages. Thus, there are 2 active mechanisms: direct inhibition of tumor cell proliferation 
by H2-R antagonists and immune reaction activation (Th1 type), characterized by IFN-
production [39,40]. 
In melanoma cells histamine stimulates human Ets-2 proto-oncogene synthesis via H2-R 
[41]. It is shown that H2-R histamine antagonists differing from H1-R histamine antagonists can 
prevent cATP concentration increase caused by histamine while H1-R  histamine antagonists are 
not as effective [42,43]. 
H1-R histamine antagonists stimulate tyrosinase activity and melanin accumulation, H2-
R histamine antagonists decrease them. Enzyme activity and pigment synthesis are accompanied 
by cell proliferation inhibition of melanoma cells. CM effectiveness exceeds that of Ranitidinum. 
H2- R histamine antagonists do not stimulate melanogenesis in A375P and C32 melanoma cells, 
but they inhibit cell proliferation in both cell lines. Thus, H2-R histamine antagonists cause 
significant phonotypical changes in malignant melanoma cells in vitro [44,45]. 
Taking into account, accumulated data about the ability of H2-R histamine antagonists to 
effect melonogenesis process as well as the process of melanoma growth and cell metastasing, 
CM is used in a combined melanoma treatment [46]. CM has improved the effectiveness of 
cytokine therapy [47]. 
Application of combined therapy of CM, surgical treatment and biotherapy with 
autovaccine in the experiment on horses did not give positive therapeutic results [48]. However, 
taking into account the progress in the field of tumor biotherapy, the CM application as an 
adjuvant agent for melanoma treatment is considered to be expedient [49]. Promising data was 
aquired for malignant vulva melanoma treatment by means of combined therapy (surgical total 
excision of tumor), biotherapy with allogenic vaccine and CM immunotherapy [50]. It opens a 
possibility to CM application for a successful therapy of melanoma as immune regulating agent 
affecting the system and local immunological and physiological processes in the course of skin 
melanoma development. 
The goal of this study is to investigate of the possibility of melanoma biotherapy 
effectiveness increase through modification of immune response in vivo using H2-receptor 
histamine antagonist (CM) as an adjuvant therapy agent for vaccinotherapy. 
MATERIALS AND METHODS. 
The research was performed in C57Bl6 male mice, 22-25 gram in weight, which were 
obtained from Animal Center (Russian Cancer Research Center, Moscow). Animals were treated 
according to the ethical guidelines of the Animal Centre, Russian Cancer Research Centre, 
Moscow. These mice were subcutaneously transplanted with melanoma cells. B16F10 mice 
melanoma cells were used which are similar to the immunophenotype of a human melanoma 
model. Growing tumors were measured twice a week, the tumor volume was calculated 
according to a formula: V=DmaxxD1x(Dmax/2), where Dmax is maximum tumor diameter, D1 is diameter 
perpendicular to the maximum one. The cells express a number of specific antigens and are characterized 
by the absence or low expression of MHC molecules. For the vaccinotherapy B16F10 BG melanoma 
GM-CSF- producing clone cells were used. They were exposed to γ-rays by Agat-R using 60Co at 
the experimental therapy clinic N.N. Blokhin Russian Cancer Research Center. Dose was 100 
gray. Vaccine was preserved in liquid nitrogen. These manipulations were necessary for 
experimental reproduction of human clinical antitumor vaccination. We used Cimetidinum 200 
mg (Pharmachim, Bulgaria). Antitumor effect was estimated by tumour growth inhibition and 
mice life span. Antimetastatic effect was evaluated by weight and number of the metastatic 
colonies in lungs according to standard techniques. Surgical operations were performed using 
gexanal anesthesia (100 mg/kg one time intra abdominal). Statistical analysis: the P values less 
than 0.05 were accepted as statistically significant. 
RESULTS AND DISCUSSION. 
48 hours later or with a delay after the formation of tumors (on 12-th days after 
transplantation B16F10 cells) mice were given CM per os five time in the doses of 25, 50 or 100 
mg/kg. After completing the 5 days therapy CM antitumor effect was estimated by comparing 
average volumes of tumor nodes in control and treated mice, and as well as the dynamics during 
the experiment. After mice deaths that resulted from tumor growth progression the influence of 
CM (as a monotherapy) on melanoma mice life span and metastasis into lungs was estimated. 
The received results are shown a table 1. 
















Control group 25,4±3,1   6,7±1,4    5/8 
CM (25 mg/kg)х5 (2-6 days) 27,1±2,4 7 5,6±2,2 38  4/7 
CМ (50 mg/kg)х5 (2-6 days) 26,4±3,3 4 5,8±0,9 9  3/7 
CM (100 mg/kg)х5 (2-6 days) 24,7±2,9 -3 5,6±2,6 17  4/8 
CM (25 mg/kg)х5 (12-16 days) 28,9±4,3 14 6,3±1,4 21  5/7 
CM (50 mg/kg)х5 (12-16 days) 26,0±3,5 2 7,1±1,7 7  3/7 
CM (100 mg/kg)х5 (12-16 days) 24,8±3,1 -3 7,7±2,2 31  5/7 
 As we can see from the table 1, CM treatment during 5 days in given doses did not result 
in significant increase of average life span of treated mice in comparison with the control group 
at early and later stages of treatment. In the course of studies of CM effectiveness on growth and 
development of melanoma cells, intensity of metastasis, it was shown that at earlier timepoints 
(on the 2-6-th days of experiment) CM application in the dose of 25 mg/kg resulted  in a slight 
inhibition of initial tumor node growth (tumor growth inhibition (TGI) = 38%). Dynamic 
observation of the average tumor node volumes in mice receiving CM in the dose 25 mg/kg has 
revealed that, the average tumor node volumes were less approximately by 1/3 in comparison 
with those in the control group. At the same time, tendency to increasing life span of the mice 
receiving CM in the dose of 25 mg/kg on the 12-16-th day of the experiment was noted. The 
average life span of these mice is 14% higher in comparison to the control (28.9±4.3 and 
25.4±3.1 days correspondingly). Interestingly, a slight decrease of metastasization levels in the 
group of mice receiving treatment was noticed in comparison with the control. The results 
stipulate good assimilation of chosen doses and treatment methods. 
In spite of the fact that these results cannot be called significant they are worth paying 
attention to and allow to consider CM as a perspective adjuvant therapy agent for melanoma 
treatment. 
Based on the previous data, for the for the next experiments with combined treatment 
with antitumor vaccine the following dose was chosen: 25 mg/kg of CM (once a day during 5 
days before vaccination; once a day during 5 days after vaccination and both (before and after) 
for different groups). Vaccination was performed 7 days before B16F10 tumor cells 
transplantation (preventive vaccination). The results are shown in Fig.1. 
Fig.1. CM effect on preventive vaccination. 
 
As we can see from the data in Fig.1, preventative vaccine application  had a significant 
effect for reducing the growth of transplanted B16F10 cells. On day 29 of the experiment at the 
transplantation locus of B16F10 cells tumors developed only in 50% of mice. The volumes of 
these tumors were less 2-3 fold than in the control group. 
Preventative vaccination along with CM treatment had more significant effect inhibiting 
tumor development. In such cases, palpable tumor nodes appeared in 66% of mice only on day 
32of the experiment. In 33% of mice tumors did not develop during 60 days; at that time they 
were under observation. The average life span of mice receiving vaccine (without taking “cured” 
ones into account) along with CM treatment was 46.0±5.7 days (p<0.05) which is 35% more 
than those in the control group; if we take into account the mice that never developed tumors and 
have been observed for 60 days it is 68% more than in the control group. The results are shown 
in Fig.2. 
Fig.2. CM influence on mice life span using preventative vaccination. 
 The results of using vaccination together with CM application for melanoma treatment 
(for treatment of already formed tumors – on the 7-th day after B16F10 cells transplantation) are 
shown in Fig.3. 
Fig.3. CM effect on vaccination for therapeutic treatment. 
 
As it is seen from the data shown above in Fig.3 the application of vaccine together with 
CM treatment had significant stimulating effect on tumor node growth. At the same time we 
cannot exclude that in this case we deal with “false” stimulation of tumor growth stipulated by 
its high infiltration by immune cells and stromal cells that hyperproliferate in the tumor growth 
zone. Our idea is also supported by the data that show the same mice life span for the control 
group (24.0±2.3 days) and the one receiving vaccine (25.2±2.1 days), as well as the mice 
receiving vaccine along with CM treatment (26.0±2.4 days). 
Because of the highly prominent immune suppression associated with high dose 
chemotherapy bone marrow transplantation is included into this experimental treatment method 
for the correction of this sideffect. Moreover, immune suppression associated with high-dose 
chemical therapy can decrease the level of premier lymphocytes, which lack cytotoxic activity. 
In this case application of immune therapy along with this therapy method could be more 
effective and have less sideffects. 
In the present research it is shown that vaccine therapy, bone marrow transplantation and 
CM treatment did not increase the effectiveness of cytotstatics alone against the tumor nodes 
(life span increasing = 87%, p<0.05 in comparison with the control group). At the same time the 
effect of Cyclophosphamide alone in high dose was not effective enough in relation to 
metastases process in lungs. Only 43% of mice that have received Cyclophosphamide had 
developed metastases. CM therapy in combination with cytotstatics, bone marrow 
transplantation and vaccinotherapy as well as CM in high dose alone as chemical therapy did not 
result in increased therapeutic effectiveness. Results are shown in Table 2. 
Table 2. Combinatory therapy effectiveness (Cyclophosphamide, bone marrow 
transplantation, antitumor whole cell GM-CSF-producing vaccine, CM treatment). 
Influence Mice quantity 
died before 







metastasis (%)  
Control group - 22,7 ± 3,5 - 0 
Vaccination  0 27,9 ± 3,7 23 14 
CM treatment 14 23,4 ± 4,1 3 0 
Vaccination + CM treatment  0 24,2 ± 2,0 6 14 
Cyclophosphamide + 
Marrow transplantation 











Vaccination + CM treatment 
0 35,0 ± 4,6 54 
(*p<0,05) 
16 
Cyclophosphamide + CM 
treatment  
0 32,6 ± 1,5 43 0 
Marrow transplantation  28 23,4 ± 4,4 3 0 
Cyclophosphamide  0 42,4 ± 6,1 87 
(*p<0,05) 
43 
Results from similar experiments using Cisplatin as chemical treatment are presented in 
Table 3. Application of Cisplatin with the following bone marrow transplantation and 
vaccination did not increase the effectiveness of Cisplatin alone similar to Cyclophosphamide 
application. At the same time application of Cisplatin in high doses increased the frequency of 
metastasis up to 57% in the treated mice group. 
Table 3. Combined therapy effectiveness (Cisplatine, bone marrow transplantation, 
antitumor whole cell GM-CSF-producing vaccine, CM treatment). 












Control group - 22,7 ± 3,5 - 16 
Vaccination 0 27,9 ± 3,7 23 14 
Cisplatin + Marrow 
transplantation+ CM 
treatment  
0 28,9 ± 2,2 27 0 
Cisplatin + Marrow 
transplantation+ 
Vaccination + CM 
treatment  
14 25,6 ± 5,9 13 14 
Cisplatin 14 29,1 ± 7,2 28 57 
Marrow transplantation 28 23,4 ± 4,4 3 0 
Acquired experimental results give us an opportunity to presume that it is necessary to 
correctly verify immune status for complex combined bio- and chemical therapies. It will allow 
creating better methods of combined therapy and increase antitumor and metastases activity. 
Summary 
1. Effectiveness of preventative antitumor whole cell GM-CSF-producing vaccine along 
with 5-time CM injection in the dose of 25 mg/kg is increased significantly. 
2. Antitumor therapies such as high dose chemical therapy, bone marrow transplantation 
and CM (histamine H2 receptors inhibitor) treatment don’t have a negative effect on 
treatment results. 
3. Treatment with CM has a regulating effect on the type and kinetics of forming immune 
reaction, which allows recommending it for subsequent research as an adjuvant drug for 
antitumor whole cell vaccination.  
 The research was made possible with financial support of Moscow Government in the 
framework of scientific and technical program “Development and implementation in medical 
practice new methods and ways of diagnostics and treatment of oncological and other diseases”.   
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